Browse > Article

Elucidation and Analysis of Desmethylsibutramine in Food  

Kwon, Chan-Hyeok (National Institute of Food and Drug Safety Evaluation)
Yoon, Tae-Hyung (National Institute of Food and Drug Safety Evaluation)
Oh, Jae-Ho (National Institute of Food and Drug Safety Evaluation)
Lee, Kwang-Ho (National Institute of Food and Drug Safety Evaluation)
Choi, Dong-Mi (National Institute of Food and Drug Safety Evaluation)
Publication Information
Journal of Food Hygiene and Safety / v.25, no.1, 2010 , pp. 30-35 More about this Journal
Abstract
It has been elucidated desmethylsibutramine in food, that is an analogue of sibutramine used for anti-obesity drug. After separating and purifying in food samples, it was analyzed and identified by the instrument such as HPLC/PDA, HPLC/MS, HPLC/MS/MS and NMR. To analyze sibutamine and desmathylsibutramine in foods, they were analyzed and identified by HPLC/PDA after extracting in dichloromethane, filtering, concentration and diluting in methanol. The overall recoveries were ranged from 87% to 91% and the limit of quantitation was $2.5\;{\mu}g/kg$. As results, sibutramine and desmethylsibutramine was not detected in all the selected 54 food samples.
Keywords
desmethylsibutramine; anti-obesity drug; food; HPLC; NMR;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ding, L., Hao, X., Hung, X., Zhang, S.: Simultaneous determination of sibutramine and its N-desmethyl metabolites in human plasma by liquid chromatography-electrospray ionization- mass spectrometry: Method and clinical applications. Anal. Chim. Acta. 492, 241-248 (2003).   DOI
2 Reedy, S.: An Evidence-Based Review of Obesity and Bariatric Surgery. J. Nurs. Pract., 5, 22-29 (2009).   DOI   ScienceOn
3 Eckel, R.: Obesity. Mechanisms and clinical management. Lippincott Williams & Wilkins, Philadelphia, PA (2003).
4 Ando, K. and Fujita, T.: Metabolic syndrome and oxidative stress. Free. Radic. Biol. Med., 47, 213-218 (2009).   DOI   ScienceOn
5 Corbalan, M., Morales, E., Canteras, M., Espallardo, A., Hernandez, T. and Garaulet, M.: Effectiveness of cognitive– behavioral therapy based on the Mediterranean diet for the treatment of obesity. Nutrition, 25, 861-869 (2009).   DOI   ScienceOn
6 Giel, K., Binkele, M., Becker, S., Stubler, P., Zipfel, S. and Enck, P.: Weight reduction and maintenance in a specialized outpatient health care center. Obes Res., 2, 143-150 (2008).
7 DeWald, T., Khaodhiar, L., Dohahue, M. and Blackbum, G.: Pharmacological and surgical treatments for obesity. Am. Heart J. 151, 604-624 (2006).   DOI   ScienceOn
8 James, W., Astrup, A., Finer, N.: Effect of sibutramine on weight maintenance after weight loss: a randomised trial. The Lancet. 356, 2119-2125 (2000).   DOI
9 Haslam, D., Phillip, W. and James, T.: Obesity. The Lancet, 366, 1197-1209 (2005).   DOI   ScienceOn
10 세계보건기구 홈페이지 (http://www.who.int).
11 강재헌: 한국인 비만유전체 관련연구, 대한임상유전체의 학회 창립기념 학술대회집, pp. 71-80 (2004).
12 살 빼는 약 바로 알고 복용하세요, 식품의약품안전청 (2007).
13 Michand, K., Forget, H. and Cohen, H.: Chronic glucocorticoid hypersecretion in Cushing's syndrome exacerbates cognitive aging. Brain and Cogn., 71, 1-8 (2009).   DOI   ScienceOn
14 Simone, G. and D'Addeo, G.: Sibutramine: Balancing weight loss benefit and possible cardiovascular risk. Nutr. Metab. Cardiovasc. Dis., 18, 337-341 (2008).   DOI   ScienceOn
15 식품의약품안전청 홈페이지 (http://www.kfda.go.kr).
16 Jeffery, J., Kerrigan, F., Miller, T., Smith, G. and Tometzi, G.: Synthesis of sibutramine, a novel cyclobutylalkylamine useful in the treatment of obesity, and its major human metabolites. J. Chem. Soc. Perkin Trans. 1, 2583-2590 (1996).
17 식품공전, 식품의약품안전청 (2008).
18 Slovacek, L., Pavlik, K. and Slovackova, B.: The effect of sibutramine therapy on occurrence of depression symptoms among obese patients. Nutr. Metab. Cardiovasc. Dis., 18, e43-e44 (2008).   DOI   ScienceOn
19 Esposito, P., Rampino, T., Gregorini, M., Soccio, G. and Canton, D.: Severe Symptomatic Hyponatremia During Sibutramine Therapy: A Case Report, 21. Am. J. Kidney Dis., 52, 137-139 (2008).   DOI   ScienceOn